FDA AdComm Meeting for NurOwn's ALS Therapy Is Critical.

Published Date: 06 Apr 2023

Natalia A. The phase 3 NurOwn pivotal trial's principal investigator, Goyal, MD, spoke about the significance of the upcoming FDA AdComm meeting and its effects on the ALS community.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Targeted radiation therapy shows near-complete response in rare sarcoma patients

2.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

3.

Germline Profiling May Improve Risk Stratification in t-MNs

4.

Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.

5.

Scientists call into question safety of potential new anticancer treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot